hVIVO plc (HVO.L)
- Previous Close
28.60 - Open
28.00 - Bid 28.20 x --
- Ask 28.50 x --
- Day's Range
28.00 - 29.00 - 52 Week Range
14.00 - 32.00 - Volume
657,823 - Avg. Volume
3,455,778 - Market Cap (intraday)
192.205M - Beta (5Y Monthly) 1.01
- PE Ratio (TTM)
14.12 - EPS (TTM)
0.02 - Earnings Date Apr 9, 2024
- Forward Dividend & Yield 0.00 (0.71%)
- Ex-Dividend Date Apr 18, 2024
- 1y Target Est
36.07
hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing of vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model. In addition, it offers specialized virology and immunology laboratory, which offers a suite of services to support pre-clinical and clinical respiratory drug; and vaccine discovery and development. Further, the company provides preclinical and early clinical research services; sales and marketing services; data management; and statistics services, as well as drug development consultancy and services. The company was formerly known as Open Orphan Plc and changed its name to hVIVO plc in October 2022. hVIVO plc is headquartered in London, the United Kingdom.
www.hvivo.comRecent News: HVO.L
Performance Overview: HVO.L
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: HVO.L
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: HVO.L
Valuation Measures
Market Cap
192.21M
Enterprise Value
167.76M
Trailing P/E
12.02
Forward P/E
21.74
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.46
Price/Book (mrq)
5.60
Enterprise Value/Revenue
2.99
Enterprise Value/EBITDA
11.97
Financial Highlights
Profitability and Income Statement
Profit Margin
27.47%
Return on Assets (ttm)
9.58%
Return on Equity (ttm)
59.09%
Revenue (ttm)
58.67M
Net Income Avi to Common (ttm)
16.11M
Diluted EPS (ttm)
0.02
Balance Sheet and Cash Flow
Total Cash (mrq)
36.97M
Total Debt/Equity (mrq)
36.50%
Levered Free Cash Flow (ttm)
9.1M
Research Analysis: HVO.L
Company Insights: HVO.L
HVO.L does not have Company Insights